Related references
Note: Only part of the references are listed.Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients
Arrigo Francesco Giuseppe Cicero et al.
INTERNAL AND EMERGENCY MEDICINE (2019)
Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis
John A. Cuenca et al.
INTERNATIONAL JOURNAL OF RHEUMATOLOGY (2019)
Relative Performance of Propensity Score Matching Strategies for Subgroup Analyses
Shirley V. Wang et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2018)
Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation
Richard J. Johnson et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2018)
Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials
Markus Bredemeier et al.
BMC CARDIOVASCULAR DISORDERS (2018)
Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study
MaryAnn Zhang et al.
CIRCULATION (2018)
Association Between Bacteremia From Specific Microbes and Subsequent Diagnosis of Colorectal Cancer
Thomas N. Y. Kwong et al.
GASTROENTEROLOGY (2018)
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert
Hyon Choi et al.
ARTHRITIS & RHEUMATOLOGY (2018)
2016 updated EULAR evidence-based recommendations for the management of gout
P. Richette et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
A review of the performance of different methods for propensity score matched subgroup analyses and a summary of their application in peer-reviewed research studies
Shirley V. Wang et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2017)
Allopurinol as a therapeutic option in cardiovascular disease
Osita N. Okafor et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis
Tony Zhang et al.
RHEUMATOLOGY (2017)
Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study
Kenneth K. C. Man et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study
Kenneth K. C. Man et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Disease Burden of Clostridium difficile Infections in Adults, Hong Kong, China, 2006-2014
Jeffery Ho et al.
EMERGING INFECTIOUS DISEASES (2017)
Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data
Jasvinder A. Singh et al.
BMC MEDICINE (2017)
Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims
Daniel H. Solomon et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study
Kasper Soltoft Larsen et al.
AMERICAN JOURNAL OF MEDICINE (2016)
Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system
K. K. C. Man et al.
TRANSLATIONAL PSYCHIATRY (2016)
Reactive Oxygen Species, Endoplasmic Reticulum Stress and Mitochondrial Dysfunction: The Link with Cardiac Arrhythmogenesis
Gary Tse et al.
FRONTIERS IN PHYSIOLOGY (2016)
Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: A Cohort Study
Seoyoung C. Kim et al.
AMERICAN JOURNAL OF MEDICINE (2015)
Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study
Michael M. Givertz et al.
CIRCULATION (2015)
Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study
Esther W. Chan et al.
GASTROENTEROLOGY (2015)
Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD)
Akira Sezai et al.
JOURNAL OF CARDIOLOGY (2015)
Improving cardiovascular and renal outcomes in gout: what should we target?
Pascal Richette et al.
NATURE REVIEWS RHEUMATOLOGY (2014)
Allopurinol Therapy in Gout Patients Does Not Associate with Beneficial Cardiovascular Outcomes: A Population-Based Matched-Cohort Study
Victor C. Kok et al.
PLOS ONE (2014)
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia
Thomas M. MacDonald et al.
BMJ OPEN (2014)
Anti-Inflammatory Treatment With Colchicine in Stable Chronic Heart Failure A Prospective, Randomized Study
Spyridon Deftereos et al.
JACC-HEART FAILURE (2014)
CArdiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular ComoRbiditiES
William B. White et al.
AMERICAN HEART JOURNAL (2012)
Xanthine Oxidase Inhibition For The Treatment Of Cardiovascular Disease: A Systematic Review and Meta-Analysis
Peter Higgins et al.
CARDIOVASCULAR THERAPEUTICS (2012)
Effect of the Treatment with Allopurinol on the Endothelial Function in Patients with Hyperuricemia
Gabriela Melendez-Ramirez et al.
ENDOCRINE RESEARCH (2012)
Serum uric acid is an independent risk factor for cardiovascular disease and mortality in hypertensive patients
Tatsuo Kawai et al.
HYPERTENSION RESEARCH (2012)
Changes in Uric Acid Levels and Allopurinol Use in Chronic Heart Failure: Association With Improved Survival
Israel Gotsman et al.
JOURNAL OF CARDIAC FAILURE (2012)
The Worldwide Environment of Cardiovascular Disease: Prevalence, Diagnosis, Therapy, and Policy Issues A Report From the American College of Cardiology
Lawrence J. Laslett et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Impact of allopurinol use on urate concentration and cardiovascular outcome
Li Wei et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Allopurinol as a Cardiovascular Drug
Anita Kelkar et al.
CARDIOLOGY IN REVIEW (2011)
Febuxostat inhibition of endothelial-bound XO: Implications for targeting vascular ROS production
Umair Z. Malik et al.
FREE RADICAL BIOLOGY AND MEDICINE (2011)
Febuxostat: a new treatment for hyperuricaemia in gout
N. Lawrence Edwards
RHEUMATOLOGY (2009)
Effects of Febuxostat Versus Allopurinol and Placebo in Reducing Serum Urate in Subjects With Hyperuricemia and Gout: A 28-Week, Phase III, Randomized, Double-Blind, Parallel-Group Trial
H. Ralph Schumacher et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: A prospective 21-year follow-up study
Alexander M. Strasak et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2008)
Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study
AD Struthers et al.
HEART (2002)